U.S. stock night market volatility: Prelude Therapeutics surged 12.24% in after-hours trading, with active capital inflow attracting market attention

U.S. Stock Night Market Movements Prelude Therapeutics rose 12.24% in the night market, with no significant news recently. Trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks with High Trading Volume in the Industry Mereo Biopharma rose 7.29% in the night market. Based on recent key news: On December 29, Mereo BioPharma announced that its two Phase III trials of setrusumab failed to meet primary endpoints, leading to a significant drop in stock price. Although the trials did not significantly reduce fracture rates, improvements were noted in bone mineral density. This news raised market concerns about the company's future profitability, with the stock price dropping over 90%. Source: MT Newswires On December 29, Mereo BioPharma stated that it is cautiously managing cash resources and immediately cutting pre-commercial and manufacturing activities. This move was interpreted by the market as the company facing financial pressure, further exacerbating stock price volatility. Source: MarketWatch On December 29, analyst Kluska downgraded optimistic expectations for Mereo stock but still believes its price could rise nearly 14 times in the next year. This analyst's viewpoint provides some confidence support to the market. Source: MarketWatch The biopharmaceutical industry has seen increased volatility recently and requires attention. BeiGene fell 1.82% in the night market. Based on recent news: On December 29, BeiGene proposed suggestions regarding drug procurement policies and innovative drug pricing at an industry association meeting. These suggestions aim to alleviate the payment pressure on basic medical insurance funds through the development of commercial health insurance and support the development of China's innovative drug industry. However, these suggestions did not receive an immediate response, leading to increased uncertainty in market expectations for future policy support for the company, affecting stock performance. On December 28, BeiGene released its latest drug development progress report. Although the company has made some progress in innovative drug development, the market remains skeptical about its ability to achieve profitability in the short term, leading to cautious investor sentiment and pressure on the stock price. On December 27, macroeconomic data was released showing a slowdown in global economic growth, particularly weak demand in major markets. This macroeconomic backdrop has negatively impacted the overall pharmaceutical industry, and as an important player in the industry, BeiGene's stock price has also been dragged down. The pharmaceutical industry faces dual challenges from policy and market demand. Recursion Pharmaceuticals rose 0.97% in the night market. Based on recent news: On December 22, Recursion Pharmaceuticals' Chief R&D Commercial Officer Najat Khan sold 124,403 shares of Class A common stock, totaling $548,592. This large transaction may have raised market concerns about insider confidence in the company, leading to stock price volatility On December 29th, Recursion Pharmaceuticals experienced a volume contraction rebound during the trading session, with short-term funds testing upward momentum, leading to a slight increase in overall sentiment in the pharmaceutical innovation sector. From a technical perspective, the bottom support is effective, and a short-term rebound may begin. On December 29th, Recursion Pharmaceuticals was caught in a low-level tug-of-war during the day, with the pharmaceutical sector overall remaining quiet, and sector fund positions being compressed. Signals of major players lurking in the community gradually emerged. Short-term main players attempted to digest selling pressure with small orders, leading to increased volatility during the session. Overall sentiment in the pharmaceutical innovation sector slightly improved, with heightened attention from short-term funds